Spectral Medical Provides Tigris Trial Update

81 patients enrolled TORONTO, Canada – December 14, 2023 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s...
Read More

Spectral Medical Provides November Tigris Trial Update

79 patients enrolled TORONTO, Canada – December 4, 2023 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update for the month of...
Read More

Spectral Medical Announces CFO Departure

TORONTO, Canada – December 1, 2023 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that Blair McInnis has provided notice of his...
Read More

Spectral Medical Provides Tigris Trial Update

76 patients enrolled Emory Healthcare latest clinical site addition into the Tigris Trial TORONTO, Canada – November 7, 2023 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for...
Read More
Click to Hide Advanced Floating Content
EAA™ and PMX are licensed and available for use in Canada. PMX is not approved for clinical use in the USA, and is currently undergoing the PMA (Premarket approval) process. EAA™ is FDA cleared for use in the USA. The information presented herein is region specific. Please contact Spectral Medical Inc.to obtain appropriate product information for your country.